Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC). In this study, we evaluated the preclinical efficacy of a third-generat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neoplasia (New York, N.Y.) N.Y.), 2020-10, Vol.22 (10), p.484-496
Hauptverfasser:	Koivisto, Christopher S., Parrish, Melodie, Bonala, Santosh B., Ngoi, Soo, Torres, Adrian, Gallagher, James, Sanchez-Hodge, Rebekah, Zeinner, Victor, Nahhas, Georges J., Liu, Bei, Cohn, David E., Backes, Floor J., Goodfellow, Paul J., Chamberlin, Helen M., Leone, Gustavo
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen receptor antagonist Endometrial carcinoma Enzalutamide Mouse model of endometrial cancer Original article Preclinical drug evaluation PTEN
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!